{
    "type": "dataset",
    "dataset_id": "7c943b09-cdae-5037-9d03-9c570b3100d0",
    "dataset_version": "1.0",
    "children": [
        {
            "type": "directory",
            "name": "Immune_repertoire_sequencing",
            "path": "Immune_repertoire_sequencing",
            "dataset_id": "7c943b09-cdae-5037-9d03-9c570b3100d0",
            "dataset_version": "1.0"
        }
    ],
    "metadata_sources": {
        "key_source_map": {
            "name": [
                "tabby"
            ],
            "description": [
                "tabby"
            ],
            "authors": [
                "tabby"
            ],
            "keywords": [
                "tabby"
            ],
            "funding": [
                "tabby"
            ],
            "publications": [
                "tabby"
            ],
            "access_request_contact": [
                "tabby"
            ],
            "additional_display": [
                "tabby"
            ]
        },
        "sources": [
            {
                "source_name": "tabby",
                "source_version": "0.1.0",
                "source_parameter": {},
                "source_time": 1716846976.628093,
                "agent_name": "Stephan Heunis",
                "agent_email": "s.heunis@fz-juelich.de"
            }
        ]
    },
    "name": "CD52-Multiple Sclerosis (MS)-immune repertoire bulk-Seq dataset",
    "description": "The dataset contains bulk sequencing data of FACS sorted B cells (naive B cells-NB; memory B cells - MB) and T cells (CD4+, CD8+) T cells  from peripheral blood mononuclear cells (PBMCs) of 12 Multiple Sclerosis (MS) patients  treated with alemtuzumab (Lemtrada) compared to  5 untreated controls. For treated patients TP1: Baseline; TP2: cycle 1 + 6 months; TP3: cycle 2 + 12 months, etc. For untreated controls TP1: m1; TP2: m6-14.",
    "authors": [
        {
            "name": "Sumanta Barman"
        },
        {
            "name": "Vera Balz"
        },
        {
            "name": "Sven G Meuth"
        },
        {
            "name": "Norbert Goebels"
        }
    ],
    "keywords": [
        "Multiple Sclerosis",
        "bulk sequencing",
        "peripheral blood", 
        "alemtuzumab"
    ],
    "funding": [
        {
            "@type": "schema:Grant",
            "name": "Genzyme Therapeutics Ltd, UK",
            "identifier": "GZ-2016-11570"
        }
    ],
    "publications": [
        {
            "@type": "schema:CreativeWork",
            "datePublished": "2022-05-01",
            "doi": "https://doi.org/10.1093/brain/awac064",
            "schema:url": "https://academic.oup.com/brain/article/145/5/1711/6590581?login=true#357455870",
            "title": "T. Ruck, S. Barman, A. Schulte-mecklenbeck, S. Pfeuffer, F. Steffen, C. Nelke, C. B. Schroeter, A. Willison, M. Heming, T. M\u00fcntefering, N. Melzer, J. Kr\u00e4mer, M. Lindner, M. Riepenhausen, C. C. Gross, L. Klotz, S. Bittner, P. A. Muraro, T. Schneider-hohendorf, N. Schwab, G. Meyer, N. Goebels, S. G. Meuth, H. Wiendl; Alemtuzumab-induced immune phenotype and repertoire change\u202f: implications for secondary autoimmunity. Brain (2022).",
            "authors": []
        },
        {
            "@type": "schema:CreativeWork",
            "doi": "",
            "title": "S. Barman, T. Ruck, V.  Balz, A. Scheffler, S. Pfeuffer, C. Lehrich, H. Wiendl, N. Melzer,  S. Meuth, N. Goebels; Dynamic Reshaping of Lymphocyte Repertoires in Multiple Sclerosis Patients Treated with Alemtuzumab: Insights into Secondary Autoimmunity.",
            "authors": []
        }
    ],
    "access_request_contact": {
        "givenName": "Sumanta",
        "familyName": "Barman",
        "email": "Sumanta.Barman@med.uni-duesseldorf.de"
    },
    "additional_display": [
        {
            "name": "ABCD-J",
            "icon": "fa-solid fa-graduation-cap",
            "content": {
                "@context": {
                    "homepage": "https://schema.org/mainEntityOfPage",
                    "data controller": "https://w3id.org/dpv#hasDataController",
                    "sample (organism)": "https://openminds.ebrains.eu/controlledTerms/Species",
                    "sample (organism part)": "https://openminds.ebrains.eu/controlledTerms/CellType",
                    "used for": "http://www.w3.org/ns/prov#hadUsage"
                },
                "sample (organism)": {
                    "@type": "https://openminds.ebrains.eu/controlledTerms/Species",
                    "name": "Homo sapiens",
                    "preferredOntologyIdentifier": "http://purl.obolibrary.org/obo/NCBITaxon_9606",
                    "synonym": "human"
                },
                "sample (organism part)": {
                    "@type": "https://openminds.ebrains.eu/controlledTerms/CellType",
                    "name": "Peripheral Blood Mononuclear Cell",
                    "preferredOntologyIdentifier": "http://purl.obolibrary.org/obo/NCIT_C12954",
                    "synonym": "PBMC"
                },
                "data controller": {
                    "@type": "https://schema.org/Person",
                    "email": "Sumanta.Barman@med.uni-duesseldorf.de",
                    "name": "Sumanta Barman"
                },
                "used for": {
                    "@type": "https://schema.org/Thing",
                    "name": "Comprehensively characterize the longitudinal changes in peripheral blood T- and B-cell repertoires pre- and post alemtuzumab treatment"
                }
            }
        }
    ]
}